Plain-English translation of NCT06287229 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a medication called brexucabtagene autoleucel, which is a type of cell therapy. The treatment uses your own immune cells, which are specially engineered in the laboratory to fight your leukemia cells. You would first receive standard chemotherapy to reduce the cancer, and then receive a single infusion of this new treatment to try to eliminate any remaining leukemia.
Acute lymphoblastic leukemia can be very difficult to treat, especially when it comes back after initial treatment or appears in high-risk forms from the start. This trial exists to see if this newer cell-based therapy can improve how long patients survive and stay cancer-free compared to what we know from current standard treatments.
You likely qualify if…
You likely don't qualify if…
You would first receive chemotherapy (either standard or reduced intensity, depending on your situation) combined with two targeted drugs to reduce your leukemia burden. After that works, you would receive lymphodepletion chemotherapy to prepare your immune system, followed by a single infusion of the new cell therapy. You would then have frequent blood draws and clinic visits over the next 24 months to monitor how well the treatment is working, how your immune system is responding, and for any side effects.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States